Transmitted Drug Resistance and Antiretroviral Treatment Outcomes in Non-Subtype B HIV-1–Infected Patients in South East Asia
暂无分享,去创建一个
S. Sirivichayakul | P. Phanuphak | R. Kantor | T. Sirisanthana | T. Merati | R. Ditangco | N. Kumarasamy | P. Kantipong | S. Sungkanuparph | A. Kamarulzaman | A. Jiamsakul | M. Lee | Christopher K. C. Lee | T. Singtoroj | W. Ratanasuwan | Mahiran Mustafa
[1] A. Sohn,et al. Transmitted HIV drug resistance in Asia , 2013, Current opinion in HIV and AIDS.
[2] F. García,et al. Analysis of transmitted drug resistance in Spain in the years 2007-2010 documents a decline in mutations to the non-nucleoside drug class. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[3] D. Pillay,et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis , 2012, The Lancet.
[4] Ann M. Dennis,et al. Prevalence of Transmitted Antiretroviral Drug Resistance Differs Between Acutely and Chronically HIV-Infected Patients , 2012, Journal of acquired immune deficiency syndromes.
[5] L. Torian,et al. Transmitted Antiretroviral Drug Resistance in New York State, 2006-2008: Results from a New Surveillance System , 2012, PloS one.
[6] M. Colafigli,et al. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] R. Paranjape,et al. Initial virologic response and HIV drug resistance among HIV-infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] F. Wit,et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. , 2012, The Lancet. Infectious diseases.
[9] W. Chantratita,et al. Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand , 2012, Journal of the International AIDS Society.
[10] C. Boucher,et al. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. , 2012, AIDS reviews.
[11] Kishor Mandaliya,et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. , 2011, The Lancet. Infectious diseases.
[12] David Dunn,et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. , 2011, The Lancet. Infectious diseases.
[13] S. Sirivichayakul,et al. Hiv-1 Drug Resistance Mutations among Antiretroviral-naive Hiv-1– Infected Patients in Asia: Results from the Treat Asia Studies to Evaluate Resistance-monitoring Study on Behalf of the Treat Asia Studies to Evaluate Resistance-monitoring Study (taser-m) , 2022 .
[14] D. Katzenstein,et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. , 2009, Journal of virological methods.
[15] Anne-Mieke Vandamme,et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.
[16] Edward P Acosta,et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.
[17] D. Bennett,et al. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania , 2008, Antiviral therapy.
[18] A. Puren,et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004 , 2008, Antiviral therapy.
[19] K. Ruxrungtham,et al. HIV drug resistance transmission threshold survey in Bangkok, Thailand , 2008, Antiviral therapy.
[20] D. Bennett,et al. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006 , 2008, Antiviral therapy.
[21] D. Bennett,et al. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam , 2008, Antiviral therapy.
[22] D. Bennett,et al. Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues. , 2008 .
[23] K. Freedberg,et al. The long‐term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model‐based approach , 2007, HIV medicine.
[24] Jörg Schüpbach,et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey , 2007, AIDS.
[25] W. Mcfarland,et al. Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance , 2006, AIDS.
[26] Tommy F. Liu,et al. Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] C. Archibald,et al. A Population-Based Approach to Determine the Prevalence of Transmitted Drug-Resistant HIV Among Recent Versus Established HIV Infections: Results From the Canadian HIV Strain and Drug Resistance Surveillance Program , 2006, Journal of acquired immune deficiency syndromes.
[28] Christine Hogan,et al. Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1: A Decade of Experience , 2006, Journal of acquired immune deficiency syndromes.
[29] M. Weinstein,et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] Tulio de Oliveira,et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..
[31] Klaus Korn,et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.
[32] C. Angeletti,et al. Cost-effectiveness analysis of using antiretroviral drug resistance testing , 2003, Scandinavian journal of infectious diseases. Supplementum.
[33] Victoria A Johnson,et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.
[35] Elena Losina,et al. Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness , 2001, Annals of Internal Medicine.